Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2017

01-10-2017 | Review Article

Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review

Authors: Marta Cremonesi, Laura Gilardi, Mahila Esmeralda Ferrari, Gaia Piperno, Laura Lavinia Travaini, Robert Timmerman, Francesca Botta, Guido Baroni, Chiara Maria Grana, Sara Ronchi, Delia Ciardo, Barbara Alicja Jereczek-Fossa, Cristina Garibaldi, Roberto Orecchia

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2017

Login to get access

Abstract

Background

Non-Small Cell Lung Cancer (NSCLC) is characterized by aggressiveness and includes the majority of thorax malignancies. The possibility of early stratification of patients as responsive and non-responsive to radiotherapy with a non-invasive method is extremely appealing. The distribution of the Fluorodeoxyglucose (18F–FDG) in tumours, provided by Positron-Emission-Tomography (PET) images, has been proved to be useful to assess the initial staging of the disease, recurrence, and response to chemotherapy and chemo-radiotherapy (CRT).

Objectives

In the last years, particular efforts have been focused on the possibility of using ad interim 18F–FDG PET (FDGint) to evaluate response already in the course of radiotherapy. However, controversial findings have been reported for various malignancies, although several results would support the use of FDGint for individual therapeutic decisions, at least in some pathologies. The objective of the present review is to assemble comprehensively the literature concerning NSCLC, to evaluate where and whether FDGint may offer predictive potential.

Methods

Several searches were completed on Medline and the Embase database, combining different keywords. Original papers published in the English language from 2005 to 2016 with studies involving FDGint in patients affected by NSCLC and treated with radiation therapy or chemo-radiotherapy only were chosen.

Results

Twenty-one studies out of 970 in Pubmed and 1256 in Embase were selected, reporting on 627 patients.

Conclusion

Certainly, the lack of univocal PET parameters was identified as a major drawback, while standardization would be required for best practice. In any case, all these papers denoted FDGint as promising and a challenging examination for early assessment of outcomes during CRT, sustaining its predictivity in lung cancer.
Literature
1.
2.
Crinò L, Weder W, van Meerbeeck J, Felip E. ESMO guidelines working group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v103–15.CrossRefPubMed
3.
Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book 2014;e353-e365
4.
Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014;15:173–81.CrossRefPubMed
5.
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.CrossRefPubMed
6.
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.CrossRefPubMed
7.
Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC, et al. PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol. 2012;81:988–1001.CrossRefPubMed
8.
Lee P, Kupelian P, Czernin J, Ghosh P. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front Oncol. 2012;11:2–7.
9.
Konert T, Vogel W, Mac Manus MP, Nestle U, Belderbos J, Grégoire V, et al. PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. Radiother Oncol. 2015;116:27–34.CrossRefPubMed
10.
Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun. 1998;19:97–105.CrossRefPubMed
11.
van Gool MH, Aukema TS, Hartemink KJ, Valdés Olmos RA, van Tinteren H, Klomp HM. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol. 2014;6:392–8.CrossRefPubMedPubMedCentral
12.
Skoura E, Datseris IE, Platis I, Oikonomopoulos G, Syrigos KN. Role of positron emission tomography in the early prediction of response to chemotherapy in patients with non-small-cell lung cancer. Clin Lung Cancer. 2012;13:181–7.CrossRefPubMed
13.
Min M, Lin P, Lee MT, Shon IH, Lin M, Forstner D, et al. Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2015;42:1984–94.CrossRefPubMedPubMedCentral
14.
Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6:112–7.CrossRefPubMed
15.
Meijer G, Steenhuijsen J, Bal M, De Jaeger K, Schuring D, Theuws J. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: practical implications of using a broad or sharp brush. Radiother Oncol. 2011;100:396–401.CrossRefPubMed
16.
Janssen MH, Öllers MC, van Stiphout RG, Riedl RG, van den Bogaard J, Buijsen J, et al. PET-based treatment response evaluation in rectal cancer: prediction and validation. Int J Radiat Oncol Biol Phys. 2012;82:871–6.CrossRefPubMed
17.
Cuenca X, Hennequin C, Hindié E, Rivera S, Vercellino L, Baruch-Hennequin V, et al. Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas. EJNMMI Res. 2013;40:477–85.
18.
Min M, Lin P, Lee M, Ho Shon I, Lin M, Forstner D, et al. Prognostic value of 2-(18)F Fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography scan carried out during and after radiation therapy for head and neck cancer using visual therapy response interpretation criteria. Clin Oncol (R Coll Radiol). 2016;28:393–401.
19.
Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628–35.CrossRefPubMed
20.
Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;54:1528–34.CrossRefPubMed
21.
Ding XP, Zhang J, Li BS, Li HS, Wang ZT, Yi Y, et al. Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. Asian Pac J Cancer Prev. 2012;13:319–23.CrossRefPubMed
22.
Bampo C, Alessi A, Fantini S, Bertarelli G, de Braud F, Bombardieri E, et al. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? Oncology. 2013;84:191–9.CrossRefPubMed
23.
Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med. 2010;51:1863–9.CrossRefPubMed
24.
Ceulemans G, Voordeckers M, Farrag A, Verdries D, Storme G, Everaert H. Can 18-FDG-PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer? Int J Radiat Oncol Biol Phys. 2011;81:938–42.
25.
De Ruysscher D, Houben A, Aerts HJ, Dehing C, Wanders R, Ollers M, et al. Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent radiation-induced lung toxicity (RILT): a prospective pilot study. Radiother Oncol. 2009;91:415–20.CrossRefPubMed
26.
Edet-Sanson A, Dubray B, Doyeux K, Hapdey S, Modzelewski R, Bohn P, et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol. 2012;102:251–7.CrossRefPubMed
27.
Thorwarth D. Hypoxia PET imaging for delineation and response assessment during radiotherapy. Radiat. Oncol. 2015;S174:SP-0362.
28.
Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I, et al. Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol. 2011;98(1):109–16.CrossRefPubMed
29.
van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400–4.PubMed
30.
Jeong JU, Chung WK, Nam TK, Song JY, Yoon MS, Kim YC, et al. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival. Anticancer Res. 2014;34:2517–23.PubMed
31.
Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31:3823–30.CrossRefPubMedPubMedCentral
32.
Xiang ZL, Erasmus J, Komaki R, Cox JD, Chang JY. FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. Radiat Oncol. 2012;7:144.CrossRefPubMedPubMedCentral
33.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.CrossRefPubMed
34.
van Baardwijk A, Bosmans G, Dekker A, van Kroonenburgh M, Boersma L, Wanders S, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother Oncol. 2007;82:145–52.CrossRefPubMed
35.
Giovacchini G, Picchio M, Schipani S, Landoni C, Gianolli L, Bettinardi V, et al. Changes in glucose metabolism during and after radiotherapy in non-small cell lung cancer. Tumori. 2009;95:177–84.PubMed
36.
Massaccesi M, Calcagni ML, Spitilli MG, Cocciolillo F, Pelligrò F, Bonomo L, et al. 18F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Radiat Oncol. 2012;7:106.CrossRefPubMedPubMedCentral
37.
Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. J Clin Oncol. 2007;25:3116–23.CrossRefPubMed
38.
Kim S, Oh SW, Kim JS, Kim KH, Kim YK. Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer. Radiat Oncol J. 2014;32:231–7.CrossRefPubMedPubMedCentral
39.
Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy. Eur J Radiol. 2011;77:92–6.CrossRefPubMed
40.
van Elmpt W, Ollers M, Dingemans AM, Lambin P, De Ruysscher D. Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med. 2012;53:1514–20.CrossRefPubMedPubMedCentral
41.
Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 2014;55:1584–90.CrossRefPubMed
42.
Vera P, Mezzani-Saillard S, Edet-Sanson A, Ménard JF, Modzelewski R, Thureau S, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging. 2014;41:1057–65.CrossRefPubMed
43.
Yossi S, Krhili S, Muratet JP, Septans AL, Campion L, Denis F, et al. Early assessment of metabolic response by 18F-FDG PET during concomitant radiochemotherapy of non-small cell lung carcinoma is associated with survival: a retrospective single-center study. Clin Nucl Med. 2015;40:e215–21.CrossRefPubMed
44.
Dong X, Sun X, Sun L, Maxim PG, Xing L, Huang Y, et al. Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer. PLoS One. 2016;11(6):e0157836.
45.
Grootjans W, Usmanij EA, Oyen WJ, van der Heijden EH, Visser EP, Visvikis D, et al. Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiother Oncol. 2016;119(3):473–9.CrossRefPubMed
46.
Gillham C, Zips D, Pönisch F, Evers C, Enghardt W, Abolmaali N, et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? Radiother Oncol. 2008;88:335–41.CrossRefPubMed
47.
Feng M, Kong FM, Gross M, Fernando S, Hayman JA, Ten Haken RK. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys. 2009;73:1228–34.CrossRefPubMedPubMedCentral
48.
Kelsey CR, Christensen JD, Chino JP, Adamson J, Ready NE, Perez BA. Adaptive planning using positron emission tomography for locally advanced lung cancer: a feasibility study. Pract Radiat Oncol. 2016;6:96–104.CrossRefPubMed
49.
Yap ML, Sun A, Higgins J, Clarke K, Marshall A, Becker N, et al. Adaptive dose escalation using serial four-dimensional positron emission tomography/computed tomography scans during radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol). 2016;28(12):e199–205.CrossRef
50.
Shirvani SM, Jiang J, Gomez DR, Chang JY, Buchholz TA, Smith BD. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer. 2013;82:252–9.CrossRefPubMed
51.
Jegadeesh N, Liu Y, Gillespie T, Fernandez F, Ramalingam S, Mikell J, et al. Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base. Clin Lung Cancer. 2016;17:398–405.
52.
Szyszko TA, Yip C, Szlosarek P, Goh V, Cook GJ. The role of new PET tracers for lung cancer. Lung Cancer. 2016;94:7–14.CrossRefPubMed
53.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–5S.CrossRefPubMedPubMedCentral
54.
Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol. 2012;19:69–77.CrossRefPubMed
55.
Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med. 2011;52(11):1690–7.CrossRefPubMedPubMedCentral
56.
Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54(1):19–26.CrossRefPubMed
57.
Ohri N, Duan F, Snyder BS, Wei B, Machtay M, Alavi A, et al. Pretreatment 18F-FDG PET textural features in locally advanced non-small cell lung cancer: secondary analysis of ACRIN 6668/RTOG 0235. J Nucl Med. 2016;57(6):842–8.CrossRefPubMedPubMedCentral
58.
Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059–66.PubMed
59.
Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardization and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.CrossRefPubMed
Metadata
Title
Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review
Authors
Marta Cremonesi
Laura Gilardi
Mahila Esmeralda Ferrari
Gaia Piperno
Laura Lavinia Travaini
Robert Timmerman
Francesca Botta
Guido Baroni
Chiara Maria Grana
Sara Ronchi
Delia Ciardo
Barbara Alicja Jereczek-Fossa
Cristina Garibaldi
Roberto Orecchia
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3762-9

Other articles of this Issue 11/2017

European Journal of Nuclear Medicine and Molecular Imaging 11/2017 Go to the issue

Original Article

Role of ICG-99mTc-nanocolloid for sentinel lymph node detection in cervical cancer: a pilot study

Original Article

The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer

Original Article

Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson

Review Article

Highlights of articles published in annals of nuclear medicine 2016

Original Article

Metabolic volume performs better than SUVmax in the detection of left ventricular assist device driveline infection

Editorial

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy